Parsian Pharmaceutical Co. Is a Major API Partner for Pharmaceutical Industry leaders Providing them with Advanced API Solutions….
Due to the change that has been occurred in human’s 21st century lifestyle, dealing with lots of daily stressors, obesity and many more life-threatening risk factors, one of the most leading cause of death and a dominant barrier to increase life expectancy in modern world is cancer. According to GLOBOCAN 2020, an estimated of 19.3 million new cancer cases (18.1 million excluding non-melanoma skin cancer) and nearly 10.0 million cancer deaths (9.9 million excluding non-melanoma skin cancer) has occurred, led cancer to ranks first or second main cause of death in nearly 112 or 183 countries and third or fourth in further 23 countries. On the basis of an estimation 1 in 3 people in the US are affected by cancer. According to the latest ranks and epidemiologic trends, cancer’s rising prominence as a leading cause of death, which leads to cardiovascular disease ranks suppressed by cancer as a dominant cause of death. According to the latest cancer estimation, Breast cancer is the most leading type of cancer, with 284,200 new cases expected in the US in 2021, the next most common cancers are lung cancer, colorectal cancer, prostate cancer, non-melanoma skin cancer and stomach. The most common causes of cancer death in 2020 were lung, colorectal, liver, stomach and breast cancer.
Targeted therapies are now new class of interest for cancer due to the advantages efficacy, selectivity and safety by acting on specific targets involved in proliferation and differentiation of cancer cells with minimal activity on normal cells compared with traditional oncologic ones. Small molecule inhibitors are one of the targeted cancer therapies, you can easily spot small molecule medicines because their generic name ends in “-ib.” By December 2020, 89 small-molecule targeted antitumor medicines have been approved by the US FDA.
Hence, one of Parsian’s biggest fields of activity is research and development in oncology to manufacture active pharmaceutical ingredients (API) and Granules of small-molecule targeted antitumor medicines along with other cancer treatments with the highest global standards to help patients battling with cancer to be cured in a better way by the latest guidelines and with the lowest adverse effects.
Diabetes is a chronic, metabolic disease that affects how your body turns food into energy, in which carbohydrate, protein, and fat metabolism is impaired. This metabolic health disorder characterized by elevated levels of blood glucose due to unstable insulin secretion, insulin resistance secretion, or both; in long-term leads to severe damage to the heart, blood vessels, nerves, eyes and kidneys. The most common type especially in adults is a diabetes mellitus type2, which occurs when the body doesn’t make enough insulin or becomes resistant to insulin. The prevalence of type 2 diabetes has risen remarkably in countries of all income levels in the last decades. Type 1 diabetes which formerly known as insulin-dependent diabetes or juvenile diabetes is a long-term health problem in which little or no insulin is produced by pancreas.
There is something about 422 million diabetic patients worldwide, most of them living in low-and middle-income countries, and leads to 1.5million deaths each year. The most considerable point is that in the last decades the number of diabetic patients and the prevalence of diabetes have been steadily increasing. According to prevalence incidence of diabetes in adults aged 18 years and older in 2014 which was around 8.5 percent globally, numerous estimates predict that the number of diabetic patients globally will be risen from 422 million to 642 million by 2040. The highest prevalence of diabetes compared to other WHO regions was belonged to the Eastern Mediterranean Region (EMRO), which was 13.7% in 2014.
Hence, one of Parsian’s fields of activity is research and development in diabetes to manufacture active pharmaceutical ingredients (API) and Granules of diabetes medicines with the highest global standards to help patients having diabetes to be cured in a better way by the latest guidelines and with the lowest adverse effects.
Multiple sclerosis represents a health condition in which immune system attacks the protective barrier (myelin) that covers nerve fibers and causes potentially disabling problems. Patients are usually affected by Multiple sclerosis at a highly productive stage of life, when people are building careers and planning families. MS can have a significant impact on affected individuals as much as their families and society.
According to National Multiple sclerosis (MS) Society study estimate, about one million people in the U.S are affected by Multiple sclerosis, which is much higher than the first national research on MS prevalence since 1975 and the last reported number. Also has been reported that 2.3 million people live with Multiple sclerosis worldwide and about 200 new cases are being diagnosed each week in the US.
Although there is a lack of ultimate cure for Multiple sclerosis, but our growing knowledge in disease-modifying therapies can make an opportunity for patients to reduce disability and extend chance of survival.
Hence, one of Parsian’s fields of activity is research and development in Multiple sclerosis to manufacture active pharmaceutical ingredients (API) and Granules of Multiple sclerosis medicines with the highest global standards to help patients having Multiple sclerosis to be cured in a better way by the latest guidelines and with the lowest adverse effects.
Thrombosis occurs when a blood clot forms inside a blood vessel, thrombosis causes blocking of the blood flow through the circulatory system and leads to serious health issues. Mostly the pathology pathway of ischemic heart disease and ischemic stroke is attributed to thrombosis, which makes thrombosis as one of the most important cause of Cardiovascular diseases. Cardiovascular diseases (CVDs) represent a group of disorders of the heart and blood vessels. Some CVDs which thrombosis is a potential cause of them are: coronary heart disease, cerebrovascular disease and peripheral arterial disease. An estimation has reported that about 17.9 million deaths each year are underlying by cardiovascular diseases, which make cardiovascular diseases (CVDs) the leading cause of death globally. Direct oral anticoagulants (DOACs) are prescribed for prevention and treatment of various cardiovascular diseases (CVDs). Recently direct oral anticoagulants (DOACs) are becoming interesting alternatives to the traditional standard of care in anticoagulation, vitamin K antagonist. Prior to 2010, the only approved oral anticoagulant on the market was warfarin, but since then that the first DOACs were approved, led DOACs to be as a leading therapeutic option, due to their better safety and effectiveness which make them more convenient treatment options for patients and clinicians in thromboembolic settings.
Hence, one of Parsian’s fields of activity is research and development in cardiovascular diseases (CVDs) to manufacture active pharmaceutical ingredients (API) and Granules of direct oral anticoagulants (DOACs) with the highest global standards to help patients having cardiovascular diseases (CVDs) to be cured in a better way by the latest guidelines and with the lowest adverse effects.
Coronavirus disease 2019 (COVID-19) represents an illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified by an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. It was initially reported to the WHO on December 31, 2019.The global COVID-19 crisis has had and will continue to have a catastrophic impact on each person globally. By over 266 million diagnosed cases globally, the COVID-19 pandemic is a worldwide health emergent issue affecting all human’s life globally. Since pandemic started various medicines have been evaluated and many of them have been prescribed for the treatment of COVID-19 despite the conflicting or preliminary results of the clinical trials. Both Favipiravir and Molnupiravir impairs SARS-CoV-2 replication, Favipiravir does it by selectively inhibiting RNA polymerase and Molnupiravir does it by increasing the frequency of viral RNA mutations. One of the distinguishing points of both of them is that they are an oral antiviral drug designed to treat COVID-19, which make them more convenient treatment options for patients. Also, on 30th December, U.S FDA panel of advisory narrowly endorses Molnupiravir for COVID-19 treatment.
Hence, one of Parsian’s fields of activity is research and development in COVID-19 to manufacture active pharmaceutical ingredients (API) and Granules of Favipiravir and Molnupiravir with the highest global standards to help patients to be cured in a better way by the latest guidelines and with the lowest adverse effects.
Amyotrophic Lateral Sclerosis (ALS) represents a progressive neuromuscular disease, often is referred to as a syndrome since the disease becomes apparent in various patterns. ALS occurrence is spontaneous and is characterized by a progressive degeneration of motor nerve cells which control voluntary muscles in the brain (upper motor neurons) and spinal cord (lower motor neurons). ALS is commonly known as Lou Gehrig’s disease. The motor neurons can no longer send impulses to the muscles, which lead to muscles atrophy and increased muscle weakness. ALS can affect anyone worldwide with no ethnic, racial or socioeconomic boundaries. In general, most patients are being diagnosed at ages of between 40 and 70, with the average of being 55 years old. The number of patients who have been affected by ALS is as many as 30,000 in the U.S, also 5,000 new cases are being diagnosed each year. According to estimates, more than five of every 100,000 deaths in people aged 20 or above are attributed to Amyotrophic Lateral Sclerosis (ALS). The prevalence incidence of ALS is about equal to multiple sclerosis and five times higher than Huntington’s disease. Up to now only four drugs have FDA-approval to treat ALS; Riluzole, Radicava, Nuedexta and Tiglutik. The one and only medicine that has been noticed in the American Academy of Neurology (AAN) guideline regarding management and care of the patient with amyotrophic lateral sclerosis (ALS), is Riluzole. The only medication that has shown efficacy in extending life in Amyotrophic Lateral Sclerosis (ALS), is Riluzole. Riluzole’s mechanism of action is not known. Pharmacologic properties include inactivation of voltage-dependent sodium channels, inhibitory effect on glutamate release and ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors.
Hence, one of Parsian’s fields of activity is research and development in ALS to manufacture active pharmaceutical ingredients (API) of ALS medicines with the highest global standards to help patients who are battling with ALS to have fewer concerns by the latest guidelines and with the lowest adverse effects.
Rheumatoid Arthritis is a systemic disease, occurs when immune system mistakenly attacks its own healthy cells, especially the lining of the joints which named by synovium or synovial membrane. Rheumatoid Arthritis affects the lining of your joints, causing a chronic painful swelling that can eventually result in joint deformity and bone erosion. Rheumatoid arthritis (RA) represents a chronic inflammatory disease that can attack more than just your joints. Sometimes Rheumatoid Arthritis’s inflammation can damage the other part of body as well, the eyes, skin, lungs, blood vessels and heart. The disease can lead to disability, decreased quality of life and premature mortality due to joint deformity and bone erosion. Each year 71 out of 100,000 persons are being diagnosed with Rheumatoid Arthritis, according to an estimate 1.5 million Americans are dealing with Rheumatoid Arthritis. Estimates show that prevalence incidence of Rheumatoid Arthritis in women is 2 or 3 times higher than men, which may it’s due to differential sexual hormones levels that play an important role in triggering or preventing it. Women generally are being diagnosed with RA between the ages of 30 and 60, which is a little bite later in men. However, Rheumatoid arthritis can present at any age, even children can develop it. Based on European Alliance of Associations for Rheumatology recommendations, following failure of one or more conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and in the presence of at least one poor prognostic factor, a biological DMARD (bDMARD) or a Janus kinase (JAK) inhibitor should be started. Tofacitinib is an oral Janus kinase (JAK) inhibitor which is approved for the treatment of RA.
Hence, one of Parsian’s fields of activity is research and development in RA to manufacture active pharmaceutical ingredients (API) of RA medicines with the highest global standards to help patients who are battling with RA to have fewer concerns by the latest guidelines and with the lowest adverse effects.
Anemia can develop a life threatening health condition in which the number of red blood cells and the hemoglobin concentration is insufficient. Hemoglobin is the main component of RBCs, which is a protein that carries oxygen to cells throughout the body. RBC synthesis takes place in the bone marrow, under the control of erythropoietin (EPO) produced by interstitial fibroblasts in the kidney. Anemia can lead to shortness of breath, cognitive dysfunction, significant fatigue, and decreased quality of life, which is associated with increased risk of cardiovascular complications, hospitalization, and death. Severe anemia is common in patients who are dealing with cancer, CKD, inflammatory diseases, myelodysplastic syndrome (MDS) and other serious health conditions. Anemia is a life threatening public health condition which specially affects young children and pregnant women. According to World Health Organization (WHO) estimates, 1.62 million people are affected by anemia, which is about 24.8% of the population globally. The highest prevalence tends to be in children less than 5 years of age, women of reproductive age and pregnant women. According to a global estimate, around 42percent of preschool-age children (i.e. those aged 6–59 months) and 40percent of pregnant women worldwide are dealing with anemia.Roxadustat could be the first in a new class of treatments called oral HIF-PH inhibitors that promotes RBC production or erythropoiesis, through increased endogenous production of EPO. Roxadustat is also in clinical development for chemotherapy-induced anemia and anemia related to MDS. Roxadustat is approved in China, Japan, Chile and South Korea, for the treatment of anemia in CKD patients. In Europe, It’s under final regulatory review following a positive EU CHMP opinion in June 2021.
Roxadustat is being commercialized and developed for the potential treatment of anemia within the US and other countries within the Americas and Australia, New Zealand and China, as well as Southeast Asia, and also is being worked for the potential treatment of anemia in Europe, Russia, Japan, Turkey and also the Commonwealth of Independent States, South Africa and therefore the Middle East.
Hence, one of Parsian’s fields of activity is research and development in Anemia to manufacture active pharmaceutical ingredient (API) of Roxadustat with the highest global standards to help patients who are battling with Anemia to have fewer concerns by the latest guidelines and with the lowest adverse effects.